This disclosure provides antibody fragments and isolated polypeptides comprising the antibody fragments that are useful as a therapeutic for those with an existing infection characterized by the formation of biofilms. Antibody fragments and isolated polypeptides comprising the antibody fragments can be administered to detect, treat, or prevent infection and/or remediate biofilms. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

The disclosure provides methods and compositions that are useful to lessen and/or cure bacterial biofilms and treat diseases or disorders associated with biofilms using one or more novel polypeptide vaccines, antibodies, antibody fragments and compositions. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air.

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

Disclosed herein are compositions and methods for sequencing, analyzing, and utilizing samples such as single samples. Also disclosed herein are compositions and methods for matching together two or more sequences from a sample. Also disclosed herein are compositions and methods for expressing and screening molecules of interest.

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

The invention relates to a recombinant Actinobacillus pleuropneumoniae toxin, having at least one epitope of Actinobacillus pleuropneumoniae toxin. When there is a plurality of the epitopes, the epitopes can be linked together with linkers. The recombinant Actinobacillus pleuropneumoniae toxin further has at least one unit of the amino acid sequence of complement C3d, and the epitopes and the amino acid sequence of complement C3d can be linked with linkers. The invention also relates to nucleotide sequences encoding the recombinant Actinobacillus pleuropneumoniae toxin and immunogenic compositions containing the recombinant Actinobacillus pleuropneumoniae toxin against porcine pleuropneumonia.

This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system.

This disclosure provides antibody fragments and isolated polypeptides comprising the antibody fragments that are useful as a therapeutic for those with an existing infection characterized by the formation of biofilms. Antibody fragments and isolated polypeptides comprising the antibody fragments can be administered to detect, treat, or prevent infection and/or remediate biofilms. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

The present disclosure relates generally to polypeptides, which may be used of the treatment of neurological diseases or disorders.